Mechanism of inhibitory effect of warfarin on mesangial cell proliferation

M Yanagita1, K Ishii, H Ozaki

  • 1Department of Geriatric Medicine, Graduate School of Medicine, Faculty of Medicine, Kyoto University, Japan.

Insights

Warfarin inhibits mesangial cell proliferation by blocking vitamin K-dependent growth factor Gas6. This finding reveals a new therapeutic strategy for glomerular diseases by targeting Gas6 gamma-carboxylation.

Area of Science:

  • Nephrology
  • Cell Biology
  • Pharmacology

Background:

  • Mesangial cell proliferation is a key feature of glomerular diseases.
  • The mechanism of warfarin's effect on mesangial proliferation is not fully understood.

Purpose of the Study:

  • To investigate if warfarin inhibits mouse mesangial cell proliferation.
  • To explore the role of Gas6 (growth arrest-specific 6) in this process.

Main Methods:

  • Examined Gas6 and Axl expression in mesangial cells.
  • Assessed the effects of exogenous Gas6 on cell proliferation and signaling pathways.
  • Investigated the impact of warfarin and vitamin K on endogenous Gas6 activity and cell proliferation.

Main Results:

  • Gas6 and its receptor Axl are expressed in mesangial cells.
  • Exogenous Gas6 promotes mesangial cell proliferation via Axl and ERK signaling.
  • Warfarin inhibited proliferation stimulated by endogenous factors in conditioned medium, an effect reversed by vitamin K.
  • Warfarin likely inhibits mesangial proliferation by interfering with Gas6 gamma-carboxylation.

Conclusions:

  • Gas6 acts as an endogenous mitogen in mesangial cells.
  • Warfarin's anti-proliferative effect on mesangial cells is mediated through the inhibition of Gas6 gamma-carboxylation.
  • This research offers insights into glomerular disease regulation and potential new therapeutic targets.

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Overview of Cell-Matrix Interactions01:24

Overview of Cell-Matrix Interactions

The extracellular matrix or ECM holds cells together to form a tissue and allows the cells within the tissue to communicate. ECM comprises proteins such as fibronectin, collagen, laminin, etc. The most abundant protein in this space is collagen. Collagen fibers are interwoven with carbohydrate-containing protein molecules called proteoglycans. ECM allows cell migration and provides a structural scaffold at cell adhesion that anchors the cell when the extracellular matrix proteins interact with...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...